Abstract
Haemostasis is a finely balanced and complex process ideally initiated only in response to disruption of the vascular endothelium as a means of preventing loss of blood from an injured vessel. Deviations from the ideal can lead to serious disease. Firstly, thrombosis, which arises as a consequence of inappropriate platelet-platelet interactions at a region of vessel damaged by atherosclerosis, can lead to occlusion of the affected vessel as in myocardial infarction or stroke. Secondly, loss of the ability of platelets to form aggregates leads to Glanzmanns thrombasthenia (GT) with a tendency to bleed for prolonged periods following injury. Glycoprotein IIb / IIIa (GPIIb / IIIa) plays a major role in the regulation of platelet adhesion and aggregation during haemostasis. Upon platelet activation by an agonist a signalling process is initiated, termed “inside-out” signalling, which gives rise to conformational changes within GPIIb / IIIa. These conformational changes increase the affinity of the receptor for its primary ligand, fibrinogen. Bound fibrinogen then acts as a bridging molecule facilitating the interaction of adjacent platelets. Upon fibrinogen binding GPIIb / IIIa undergoes further conformational changes and through a process termed “outside-in” signalling the receptor signals in to the platelet ultimately resulting in acceleration of the aggregation process. Qualitative or quantitative abnormalities in GPIIb / IIIa give rise to GT, a recessive bleeding disorder, and analysis of affected individuals has provided invaluable insights into the structure / function relationship of this receptor. Due to its critical role in mediating platelet aggregate formation GPIIb / IIIa has become a primary target for the development of antithrombotic agents.
Keywords: platelet glycoprotein IIb/IIIa, thrombosis, haemostasis, atherosclerosis, glanzmann thrombasthenia
Current Pharmaceutical Design
Title: The Role of the Platelet Glycoprotein IIb / IIIa in Thrombosis and Haemostasis
Volume: 10 Issue: 14
Author(s): John F. Fullard
Affiliation:
Keywords: platelet glycoprotein IIb/IIIa, thrombosis, haemostasis, atherosclerosis, glanzmann thrombasthenia
Abstract: Haemostasis is a finely balanced and complex process ideally initiated only in response to disruption of the vascular endothelium as a means of preventing loss of blood from an injured vessel. Deviations from the ideal can lead to serious disease. Firstly, thrombosis, which arises as a consequence of inappropriate platelet-platelet interactions at a region of vessel damaged by atherosclerosis, can lead to occlusion of the affected vessel as in myocardial infarction or stroke. Secondly, loss of the ability of platelets to form aggregates leads to Glanzmanns thrombasthenia (GT) with a tendency to bleed for prolonged periods following injury. Glycoprotein IIb / IIIa (GPIIb / IIIa) plays a major role in the regulation of platelet adhesion and aggregation during haemostasis. Upon platelet activation by an agonist a signalling process is initiated, termed “inside-out” signalling, which gives rise to conformational changes within GPIIb / IIIa. These conformational changes increase the affinity of the receptor for its primary ligand, fibrinogen. Bound fibrinogen then acts as a bridging molecule facilitating the interaction of adjacent platelets. Upon fibrinogen binding GPIIb / IIIa undergoes further conformational changes and through a process termed “outside-in” signalling the receptor signals in to the platelet ultimately resulting in acceleration of the aggregation process. Qualitative or quantitative abnormalities in GPIIb / IIIa give rise to GT, a recessive bleeding disorder, and analysis of affected individuals has provided invaluable insights into the structure / function relationship of this receptor. Due to its critical role in mediating platelet aggregate formation GPIIb / IIIa has become a primary target for the development of antithrombotic agents.
Export Options
About this article
Cite this article as:
Fullard F. John, The Role of the Platelet Glycoprotein IIb / IIIa in Thrombosis and Haemostasis, Current Pharmaceutical Design 2004; 10 (14) . https://dx.doi.org/10.2174/1381612043384682
DOI https://dx.doi.org/10.2174/1381612043384682 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Nitrosative Stress and Peroxynitrite in the Pathogenesis of Diabetic Complications. Emerging New Therapeutical Strategies
Current Medicinal Chemistry Procyanidins and Their Healthy Protective Effects Against Type 2 Diabetes
Current Medicinal Chemistry Recent Software Developments and Applications in Functional Imaging
Current Pharmaceutical Biotechnology The Management of Vesico Vaginal Fistulae
Current Women`s Health Reviews State of the Art Management of Transfusion-Related Acute Lung Injury (TRALI)
Current Pharmaceutical Design Injectable <i>In-Situ</i> Forming Depot of Doxycycline Hyclate/α-Cyclodextrin Complex Using PLGA for Periodontitis Treatment: Preparation, Characterization, and <i>In-Vitro</i> Evaluation
Current Drug Delivery Alterations in the Vascular Reactivity of Aorta in the Early and Late Phase of Adjuvant-Induced Arthritis in Rat
Vascular Disease Prevention (Discontinued) Applications of FDG-PET/CT in Assessment of Vascular Infection and Inflammation
Current Molecular Imaging (Discontinued) Leptin and Vascular Smooth Muscle
Current Vascular Pharmacology The Relationship Between Inflammation and the Anticoagulant Pathway: The Emerging Role of Endothelial Nitric Oxide Synthase (eNOS)
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Drug Targets Ischemic Strokes in Congenital Bleeding Disorders: Comparison with Myocardial Infarction and other Acute Coronary Syndromes
Cardiovascular & Hematological Disorders-Drug Targets Analysis of Glycosaminoglycans by Electrophoretic Approach
Current Pharmaceutical Analysis Micro Composite Palmitoylethanolamide/Rutin Reduces Vascular Injury through Modulation of the Nrf2/HO−1 and NF-kB Pathways
Current Medicinal Chemistry Enhanced Free Radical Status of Cancer Cells Success and Failure of Prooxidant/Antioxidant Treatment
Current Signal Transduction Therapy Toll-Like Receptors: Link between “Danger” Ligands and Plaque Instability
Current Drug Targets Serpin Regulation of Fibrinolytic System: Implications for Therapeutic Applications in Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Update on the Important New Drug Target in Cardiovascular Medicine – the Vascular Glycocalyx
Cardiovascular & Hematological Disorders-Drug Targets Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Current Neuropharmacology Metabolic Syndrome and Non-Cardiac Vascular Diseases: An Update from Human Studies
Current Pharmaceutical Design